TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17520888

Group type: EXPERIMENTAL
Intervention: Emoxypine (150 mg every day for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mexidol (300 mg a day for 14 days)
Number of subjects: 0
Study: 15355528

Group type: EXPERIMENTAL
Intervention: VIPS implementation programme (study group)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Regular 3-day documentation course (control group)
Number of subjects: 129
Study: 11972430

Group type: EXPERIMENTAL
Intervention: Single-course glucocorticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated courses of glucocorticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to glucocorticoids
Number of subjects: 0
Study: 9587910

Group type: EXPERIMENTAL
Intervention: Microwave radiation exposure (6-12 GHz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8308619

Group type: EXPERIMENTAL
Intervention: Midazolam alone
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Midazolam-midazolam
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam-methohexital
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 3370199

Group type: EXPERIMENTAL
Intervention: Vacuum aspiration
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Gemeprost (1 mg vaginal pessary every 3 h for up to 5 pessaries)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: RU 486 (150 mg per day for 4 days)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: RU 486 (150 mg per day for 4 days) plus Gemeprost (1 mg on day 3)
Number of subjects: 97

Group type: COMPARATOR
Intervention: RU 486 alone
Number of subjects: 97
Study: 30798472

Group type: EXPERIMENTAL
Intervention: Magnesium oxide 500 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Valproate sodium 400 mg
Number of subjects: 63
Study: 31102145

Group type: EXPERIMENTAL
Intervention: Adjuvant bevacizumab with oxaliplatin-based chemotherapy
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Standard oxaliplatin-based chemotherapy regimens
Number of subjects: 1226
Study: 28916436

Group type: EXPERIMENTAL
Intervention: Combination therapy (solifenacin 5mg and mirabegron 25mg, increased to 50mg at week 4)
Number of subjects: 2110

Group type: COMPARATOR
Intervention: Solifenacin 5mg
Number of subjects: 2110

Group type: COMPARATOR
Intervention: Solifenacin 10mg
Number of subjects: 2110
Study: 26126306

Group type: EXPERIMENTAL
Intervention: Single-use negative pressure wound therapy (NPWT) system
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control cohort (historical)
Number of subjects: 110
Study: 23932641

Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 291
Study: 21057704

Group type: EXPERIMENTAL
Intervention: MP-TF activity before chemotherapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: MP-TF activity after chemotherapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: MP-TF activity in patients who developed VTE
Number of subjects: 122

Group type: COMPARATOR
Intervention: MP-TF activity in patients who did not develop VTE
Number of subjects: 122
Study: 18455586

Group type: EXPERIMENTAL
Intervention: Total arterial revascularization (161 patients)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Conventional revascularization (170 patients)
Number of subjects: 331
Study: 17006119

Group type: EXPERIMENTAL
Intervention: 4% endotracheal tube cuff lignocaine
Number of subjects: 82

Group type: COMPARATOR
Intervention: 1.5 mg/kg intravenous lignocaine
Number of subjects: 82
Study: 15002860

Group type: EXPERIMENTAL
Intervention: Listening to Mozart's Sonata for Two Pianos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various conditions (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal Reasoning condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spatial Reasoning condition
Number of subjects: 0
Study: 11052464

Group type: EXPERIMENTAL
Intervention: Bone meal powder (BEC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium carbonate (CAC)
Number of subjects: 12
Study: 8804333

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Episodic infusion
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Prophylactic care
Number of subjects: 97
Study: 1535359

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Treatment (SMT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham Manipulation
Number of subjects: 45
Study: 6386484

Group type: EXPERIMENTAL
Intervention: 400 mg etozolin (E)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 40 mg furosemide (F)
Number of subjects: 17
Study: 31953630

Group type: EXPERIMENTAL
Intervention: Go intervention group (IG) attending 12 Go lessons
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CG) attending health education lectures
Number of subjects: 18
Study: 31397289

Group type: EXPERIMENTAL
Intervention: Bimagrumab 10 mg/kg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Bimagrumab 3 mg/kg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Bimagrumab 1 mg/kg
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Bimagrumab (all doses)
Number of subjects: 251
Study: 28151742

Group type: EXPERIMENTAL
Intervention: First trimester weight gain trajectory (measured in SD increases above predicted gain)
Number of subjects: 124590

Group type: EXPERIMENTAL
Intervention: Second trimester weight gain trajectory
Number of subjects: 124590

Group type: EXPERIMENTAL
Intervention: Weight gain trajectory by prepregnancy BMI category
Number of subjects: 124590
Study: 27052266

Group type: EXPERIMENTAL
Intervention: 4RIF (rifampin for 4 months)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 9INH (isoniazid for 9 months)
Number of subjects: 189

Group type: COMPARATOR
Intervention: TST positive
Number of subjects: 189

Group type: COMPARATOR
Intervention: QFT-G positive
Number of subjects: 189

Group type: COMPARATOR
Intervention: LTBI treatment acceptance
Number of subjects: 189
Study: 25171686

Group type: EXPERIMENTAL
Intervention: intelligent volume-assured pressure support (iVAPS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: high-intensity noninvasive positive-pressure ventilation (HI-NPPV)
Number of subjects: 14
Study: 21806683

Group type: EXPERIMENTAL
Intervention: 3 weeks of undisturbed plaque accumulation
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3 weeks of optimal plaque control
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CF levels of MMP-8
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CF levels of IL-1β
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Total DNA counts
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Detection frequency of putative periodontal pathogens
Number of subjects: 15
Study: 20232769

Group type: EXPERIMENTAL
Intervention: SIT with Phleum pratense
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group without SIT
Number of subjects: 46
Study: 17437728

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 479

Group type: COMPARATOR
Intervention: Aspirin plus thienopyridine
Number of subjects: 479
Study: 16416663

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg IM one hr before surgery (Group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg into the surgical site (Group B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg IM one hr before surgery plus 50 mg into the surgical site (Group C)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 48
Study: 12503833

Group type: EXPERIMENTAL
Intervention: SPO2 80%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SPO2 90%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (SPO2 > 97%)
Number of subjects: 12
Study: 9845561

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg twice daily for 1 week
Number of subjects: 77
Study: 7862837

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2644129

Group type: EXPERIMENTAL
Intervention: High-dose Ara-C (3 g/m2 every 12 hours during 3 h of infusion)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Addition of standard maintenance treatment after consolidation with 4 courses of DAT (Daunorubicin + Ara-C + 6-Thioguanine)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: High-dose Ara-C
Number of subjects: 125
Study: 301745

Group type: EXPERIMENTAL
Intervention: Diflunisal (acute single dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diflunisal (chronic multiple dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diflunisal (high dosage open study)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (acute single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (chronic multiple dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (high dosage open study)
Number of subjects: 20
Study: 30878156

Group type: EXPERIMENTAL
Intervention: Food Addiction (FA)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Poor Sleep Quality
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Chronotype Distribution
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Correlations with YFAS score
Number of subjects: 644
Study: 30681352

Group type: EXPERIMENTAL
Intervention: Fractured limbs of case horses
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Nonfractured limbs of case horses
Number of subjects: 114

Group type: COMPARATOR
Intervention: Limbs of control horses
Number of subjects: 114
Study: 29048511

Group type: EXPERIMENTAL
Intervention: Implementation of the 2011 national guidelines on antibiotic prescriptions for ARTI, including local protocol implementation, education sessions, and feedback.
Number of subjects: 242534

Group type: EXPERIMENTAL
Intervention: Implementation of the 2011 national guidelines on antibiotic prescriptions for ARTI.
Number of subjects: 242534
Study: 25728688

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention for PTSS, depression, and anxiety (10-week program based on cognitive behavior therapy)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention for depression and anxiety
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 58
Study: 23742144

Group type: EXPERIMENTAL
Intervention: Multiparametric score based on clinical status, echo Doppler variables, NT-proBNP, eGFR, and drug therapies.
Number of subjects: 638
Study: 21767341

Group type: EXPERIMENTAL
Intervention: Prandial insulin aspart three times daily
Number of subjects: 708

Group type: COMPARATOR
Intervention: Biphasic insulin aspart twice‐daily
Number of subjects: 708

Group type: COMPARATOR
Intervention: Basal insulin detemir once‐daily (twice if required)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: BMI gain > 1.23 kg/m²
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Occurrence of hypoglycaemia
Number of subjects: 708
Study: 19957839

Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Open discectomy (OD)
Number of subjects: 215
Study: 16978619

Group type: EXPERIMENTAL
Intervention: Letrozole + rFSH
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clomiphene Citrate + rFSH
Number of subjects: 41
Study: 15133775

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch, nicotine gum, or bupropion (33-50% of patients)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Higher quitting self-efficacy, risk perceptions, and perceived benefits of quitting
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Lower tobacco use and nicotine addiction, shorter time since diagnosis
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Depressive symptoms, low quitting self-efficacy, low perceived risk, low perceived benefits of quitting
Number of subjects: 111
Study: 11126337

Group type: EXPERIMENTAL
Intervention: Yoghurt containing a novel fat emulsion (5g of a novel fat emulsion + 1g milk fat)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control yoghurt (6g milk fat)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Yoghurt containing a novel fat emulsion
Number of subjects: 59
Study: 9145142

Group type: EXPERIMENTAL
Intervention: Selective delay TRAM flap
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard TRAM flap
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Delayed TRAM flap
Number of subjects: 28
Study: 8437976

Group type: EXPERIMENTAL
Intervention: Theophylline short-term infusion (420 mg theophylline)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aminophylline short-term infusion (theophylline component 351.3 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline and aminophylline infusions
Number of subjects: 16
Study: 3511103

Group type: EXPERIMENTAL
Intervention: 0.01% Sanguinarine mouthwash
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouthwash
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 21
Study: 30854916

Group type: EXPERIMENTAL
Intervention: Ashwagandha extract (Shoden beads, 21 mg of withanolide glycosides per day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 30110693

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily with tramadol hydrochloride 50 mg twice daily (as required)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Tramadol hydrochloride 50 mg twice daily for 6 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 72
Study: 26345262

Group type: COMPARATOR
Intervention: Usual care group (post-ICD implantation)
Number of subjects: 42
Study: 24901856

Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole, amoxicillin, and metronidazole)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole, tetracycline, metronidazole, and bismuth subcitrate)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Overall treatment (both therapies combined)
Number of subjects: 55
Study: 22618567

Group type: EXPERIMENTAL
Intervention: stavudine-lamivudine-nevirapine (d4T/3TC/NVP)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: stavudine-lamivudine-efavirenz (d4T/3TC/EFV)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: NVP
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: EFV
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: N348I in the context of polymerase domain mutations
Number of subjects: 63
Study: 20183706

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial skills in women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spatial skills in men
Number of subjects: 0
Study: 17984816

Group type: EXPERIMENTAL
Intervention: Hib‐MenC‐TT vaccine
Number of subjects: 100
Study: 15691312

Group type: EXPERIMENTAL
Intervention: Second-line triple therapy (7 days of omeprazole, amoxicillin and clarithromycin twice a day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Second-line quadruple therapy (7 days of omeprazole twice a day, plus tetracycline, metronidazole and bismuth subcitrate three times a day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Triple first strategy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Quadruple first strategy
Number of subjects: 49
Study: 11836733

Group type: EXPERIMENTAL
Intervention: Common methods of analysis for count data in the presence of selection criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from an epilepsy trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from a study of transient myocardial ischaemia
Number of subjects: 0
Study: 9706929

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (10 microg/kg i.m. 15 min before anesthesia)
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Intravenous fluids (lactated Ringer's solution 15 mL/kg within 15 min before spinal anesthesia)
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Intraoperative application of both sedatives and opioids (subgroup)
Number of subjects: 1066
Study: 7620695

Group type: EXPERIMENTAL
Intervention: Bevantolol hydrochloride
Number of subjects: 24
Study: 2490833

Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 10940

Group type: COMPARATOR
Intervention: Referred care
Number of subjects: 10940
Study: 336818

Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine (S-CMC; Mucodyne, Berk Pharmaceuticals)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 52
Study: 31652226

Group type: EXPERIMENTAL
Intervention: Intralesional cryosurgery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 31
Study: 30888743

Group type: EXPERIMENTAL
Intervention: Volatile anesthetics (desflurane, isoflurane, or sevoflurane)
Number of subjects: 5400

Group type: COMPARATOR
Intervention: Total intravenous anesthesia
Number of subjects: 5400
Study: 28569455

Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Specific strength training (ST)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (Con)
Number of subjects: 34
Study: 25900169

Group type: EXPERIMENTAL
Intervention: Universal glove and gown use during all patient contact in ICUs
Number of subjects: 1800
Study: 23838159

Group type: EXPERIMENTAL
Intervention: r-FSH and r-LH (Luveris 150 IU/day)
Number of subjects: 253

Group type: COMPARATOR
Intervention: r-FSH only
Number of subjects: 253
Study: 21217461

Group type: EXPERIMENTAL
Intervention: Repetitive locomotor training with an electromechanical gait trainer (Gait Trainer GT I) plus 10 mins of passive joint mobilization and stretching exercises
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 18
Study: 19190781

Group type: EXPERIMENTAL
Intervention: Azithromycin (mass distribution)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Post-treatment observation
Number of subjects: 16
Study: 16417762

Group type: EXPERIMENTAL
Intervention: Vertical banded gastroplasty (VBG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lap-Band surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study: 15486960

Group type: EXPERIMENTAL
Intervention: Quetiapine (Seroquel)
Number of subjects: 1106
Study: 11318837

Group type: COMPARATOR
Intervention: No retinopathy
Number of subjects: 3709

Group type: COMPARATOR
Intervention: Microaneurysms (MA) in one eye only
Number of subjects: 3709

Group type: EXPERIMENTAL
Intervention: More severe retinopathy features
Number of subjects: 3709

Group type: COMPARATOR
Intervention: No retinopathy at 6 years
Number of subjects: 3709

Group type: EXPERIMENTAL
Intervention: More severe retinopathy
Number of subjects: 3709
Study: 9643620

Group type: EXPERIMENTAL
Intervention: Intravenous bambuterol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous terbutaline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral bambuterol (single dose and repeated doses once daily for 7 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Generated terbutaline from oral bambuterol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Repeated oral dosing of bambuterol
Number of subjects: 8
Study: 7945745

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP, 0.5 mg/kg p.o.)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: L-tryptophan (L-TRP, 100 mg/kg i.v.)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: L-tryptophan (L-TRP)
Number of subjects: 43
Study: 3074860

Group type: EXPERIMENTAL
Intervention: Behavioural Intervention Enactive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioural Intervention Symbolic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education Only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-EE groups (Education Only and Routine Treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-EE relatives (no active intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioural Intervention groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education Only and Routine Treatment groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study: 29083501

Group type: EXPERIMENTAL
Intervention: DESMOND-ID programme (n = 19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 39
Study: 27010635

Group type: COMPARATOR
Intervention: Coffee consumption >3 to 7 cups/day
Number of subjects: 91767

Group type: COMPARATOR
Intervention: Coffee consumption >7 cups/day
Number of subjects: 91767

Group type: COMPARATOR
Intervention: Coffee consumption >5 cups/day in never smokers
Number of subjects: 91767

Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 91767
Study: 26242644

Group type: EXPERIMENTAL
Intervention: Primary care (n=391)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Secondary care (n=390)
Number of subjects: 781
Study: 23763412

Group type: EXPERIMENTAL
Intervention: Stress-focused sexual risk reduction intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: General health promotion intervention
Number of subjects: 0
Study: 20581214

Group type: EXPERIMENTAL
Intervention: Oral celecoxib from the evening before surgery until 48 hours after operation.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo from the evening before surgery until 48 hours after operation.
Number of subjects: 40
Study: 18346185

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1913
Study: 16901414

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study: 14649342

Group type: EXPERIMENTAL
Intervention: Paravertebral nerve blockade
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60